JHJesus Turró Homedes

Jesus Turró Homedes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jesus Turró Homedes has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Endoscopic Gastric Mega-plication (MEGA) for the Primary Treatment of Obesity: “A European Multicenter Retrospective Cohort Study, 6-month Outcomes”

    by Román Turró Araú, Gherzon Casanova Rimer, Antonio Ortega Sabater, Ivo Boskoski, Milutin Bulajic, Jan Willem Greve, Karl Miller, Sebastian Teschers, Juan Colán-Hernández, Laura García Moldón, et al.

    Background Obesity is a chronic and highly prevalent disease. Although bariatric surgery is the most effective treatment, access remains limited. Endoscopic bariatric therapies have emerged as minimally invasive alternatives. MEGA (Endoscopic Gastric Megaplication) is a modified version of POSE 2.0 that uses two G-LIX devices, a 33-mm G-PROX, and fewer sutures (mean: six) to create double gastric plications, with the goal of streamlining the procedure. Objective To evaluate the technical reproducibility, clinical efficacy, and safety of the MEGA technique at 6 months in a multicenter cohort of patients with obesity, and to explore inter-center variability and correlations between technical and clinical outcomes. Methods This retrospective multicenter cohort study included 54 patients with BMI (kg/m²) ≥ 27and comorbidities or BMI ≥ 30, treated with MEGA across six European centers experienced in bariatric endoscopy. Procedures were performed by local endoscopists after standardized training by a single instructor. Technical variables (number of sutures, procedure time) and clinical outcomes (%TBWL, %EBWL) were analyzed. Results At 6 months, mean %TBWL was 14.75 ± 6.24% (95% CI:13.05–16.45), and mean %EBWL was 56.17 ± 33.75% (95% CI: 46.96–65.39), with no significant differences among centers (p = 0.406). Overall, 81.5% of patients (95% CI: 69.2–89.6) achieved ≥ 10% TBWL. No serious adverse events were reported. No correlation was found between number of sutures and %TBWL. Conclusion In this preliminary multicenter study with 6-month follow-up, the MEGA technique was associated with clinically meaningful weight loss and no serious adverse events. Larger prospective studies with long-term follow-up are needed.

  • Open Access

    Aspiration Therapy As a Tool to Treat Obesity: 1- to 4-Year Results in a 201-Patient Multi-Center Post-Market European Registry Study

    by Max Nyström, Evzen Machytka, Erik Norén, Pier Alberto Testoni, Ignace Janssen, Jesus Turró Homedes, Jorge Carlos Espinos Perez, Roman Turro Arau

    Purpose The objective of this post-market study was to evaluate long-term safety and efficacy of aspiration therapy (AT) in a clinical setting in five European clinics. Materials and Methods The AspireAssist® System (Aspire Bariatrics, Inc. King of Prussia, PA) is an endoscopic weight loss therapy utilizing a customized percutaneous endoscopic gastrostomy tube and an external device to aspirate approximately 30% of ingested calories after a meal, in conjunction with lifestyle counseling. A total of 201 participants, with body mass index (BMI) of 35.0–70.0 kg/m2, were enrolled in this study from June 2012 to December 2016. Mean baseline BMI was 43.6 ± 7.2 kg/m2. Results Mean percent total weight loss at 1, 2, 3, and 4 years, respectively, was 18.2% ± 9.4% (n/N = 155/173), 19.8% ± 11.3% (n/N = 82/114), 21.3% ± 9.6% (n/N = 24/43), and 19.2% ± 13.1% (n/N = 12/30), where n is the number of measured participants and N is the number of participants in the absence of withdrawals or lost to follow-up. Clinically significant reductions in glycated hemoglobin (HbA1C), triglycerides, and blood pressure were observed. For participants with diabetes, HbA1C decreased by 1% (P < 0.0001) from 7.8% at baseline to 6.8% at 1 year. The only serious complications were buried bumpers, experienced by seven participants and resolved by removal/replacement of the A-Tube, and a single case of peritonitis, resolved with a 2-day course of intravenous antibiotics. Conclusion This study establishes that aspiration therapy is a safe, effective, and durable weight loss therapy in people with classes II and III obesity in a clinical setting. Trial Registration ISRCTN 49958132